Paul Baldrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Paul Baldrick has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- James W. Hutchings
Allergy Therapeutics (UK) Ltd, Dominion Way, Worthing, West Sussex, BN14 8SA, England, UK
2 shared publications Lesley Reeve
Regulatory Strategy, Global Regulatory Affairs, Covance, Harrogate, United Kingdom
2 shared publications- Matthew D. Heath
Allergy Therapeutics PLC Worthing UK
2 shared publications Murray A. Skinner
Allergy Therapeutics (UK) Ltd, Dominion Way, Worthing, West Sussex, BN14 8SA, England, UK
2 shared publications- Andreas Reichl
Labcorp Drug Development Inc., headquarters in Burlington North Carolina USA
1 shared publication Chris Gray
Covance Laboratories Ltd, Harrogate, North Yorkshire, UK
1 shared publication
Latest Publications
- 27 February 2026
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 168, 106076
Oncology drugs: Target organ findings seen in animal toxicity testing
- 27 February 2026
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 168, 106076
Oncology drugs: Target organ findings seen in animal toxicity testing
- 26 December 2022
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 42 (2) , 122-134
Nonclinical Testing Evaluation of Liposomes as Drug Delivery Systems
Various marketed drugs, as well as many in-development, have utilized liposomes, vesicles composed of one or more phospholipid bilayers, as a drug delivery system, often with the statement that they are “non-toxic” materials. This paper examined safety testing considerations and reviewed nonclinical packages used to support the safe clinical use and marketing of drugs using a liposomal drug delivery system, including liposome-only study findings. It was found that most experience has come from use of an established drug (especially in the oncology field) in a liposome formulation with known excipients. From this knowledge, it is proposed that the minimal package of studies (using an oncology indication as an example) needed to support clinical entry should include in vivo pharmacology in selected mouse xenograft models, pharmacokinetic characterization showing enhanced kinetics or disposition and including tumor exposure evaluation along with repeat-dose toxicity testing in one species. It was also found that the liposomes used in drug delivery systems are not truly “non-toxic” materials. However, the majority of findings in toxicity testing relate to macrophage processing of large amounts of lipid material, with no human known safety consequence. Of note, however, are cases of hypersensitivity for some PEGylated liposome forms which translate to the clinic.
- 26 December 2022
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 42 (2) , 122-134
Nonclinical Testing Evaluation of Liposomes as Drug Delivery Systems
Various marketed drugs, as well as many in-development, have utilized liposomes, vesicles composed of one or more phospholipid bilayers, as a drug delivery system, often with the statement that they are “non-toxic” materials. This paper examined safety testing considerations and reviewed nonclinical packages used to support the safe clinical use and marketing of drugs using a liposomal drug delivery system, including liposome-only study findings. It was found that most experience has come from use of an established drug (especially in the oncology field) in a liposome formulation with known excipients. From this knowledge, it is proposed that the minimal package of studies (using an oncology indication as an example) needed to support clinical entry should include in vivo pharmacology in selected mouse xenograft models, pharmacokinetic characterization showing enhanced kinetics or disposition and including tumor exposure evaluation along with repeat-dose toxicity testing in one species. It was also found that the liposomes used in drug delivery systems are not truly “non-toxic” materials. However, the majority of findings in toxicity testing relate to macrophage processing of large amounts of lipid material, with no human known safety consequence. Of note, however, are cases of hypersensitivity for some PEGylated liposome forms which translate to the clinic.
- 21 May 2022
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 132, 105189
Development of COVID-19 therapies: Nonclinical testing considerations
- 21 May 2022
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 132, 105189
Development of COVID-19 therapies: Nonclinical testing considerations
- 4 February 2022
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 130, 105130
Successful regulatory agency interaction – A nonclinical regulatory strategist's perspective
- 4 February 2022
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 130, 105130
Successful regulatory agency interaction – A nonclinical regulatory strategist's perspective
- 1 August 2021
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 868-869, 503388
Genotoxicity test battery – An assessment of its utility in early drug development
- 1 August 2021
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 868-869, 503388
Genotoxicity test battery – An assessment of its utility in early drug development
- 1 May 2021
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 109, 107055
Core battery safety pharmacology testing – An assessment of its utility in early drug development
- 1 May 2021
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 109, 107055
Core battery safety pharmacology testing – An assessment of its utility in early drug development
- 1 April 2021
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 121, 104869
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies
- 1 April 2021
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 121, 104869
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies
- 24 August 2020
- Published by Wiley in Journal of Applied Toxicology
- Vol. 41 (1) , 95-104
Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals
Drug development includes imaging agents, contrast agents and radiopharmaceuticals; these materials differ from therapeutic drugs in that they are largely used to diagnose and/or monitor diseases and not treat them. Consequently, nonclinical safety testing needs are different. An examination of testing packages supporting clinical entry and/or marketing of these materials has shown a common approach to some study types (eg, imaging, biodistribution and toxicity testing). Recent regulatory guidelines to support development are the United States Food and Drug Administration (FDA)’s “Guidance for Industry Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations” and the European Medicines Agency (EMA)’s “Guideline on the Non‐Clinical Requirements for Radiopharmaceuticals” (currently draft). It is hoped that these documents will allow developers to only perform nonclinical studies that are necessary to support functionality, follow distribution of the material and examine general safety/toxicity. However, as they are mainly focused on radiopharmaceuticals, companies are likely to apply knowledge of established testing packages to other new imaging agents and/or follow principles given in older regulatory guidelines, namely FDA’s “Guidance for Industry Developing Medical Imaging Drug and Biological Products Part I Conducting Safety Assessments”. Thus, in some cases, the need for regulatory agency interaction is still vital to avoid development surprises and delays due to an incomplete or badly performed testing package.
- 24 August 2020
- Published by Wiley in Journal of Applied Toxicology
- Vol. 41 (1) , 95-104
Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals
Drug development includes imaging agents, contrast agents and radiopharmaceuticals; these materials differ from therapeutic drugs in that they are largely used to diagnose and/or monitor diseases and not treat them. Consequently, nonclinical safety testing needs are different. An examination of testing packages supporting clinical entry and/or marketing of these materials has shown a common approach to some study types (eg, imaging, biodistribution and toxicity testing). Recent regulatory guidelines to support development are the United States Food and Drug Administration (FDA)’s “Guidance for Industry Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations” and the European Medicines Agency (EMA)’s “Guideline on the Non‐Clinical Requirements for Radiopharmaceuticals” (currently draft). It is hoped that these documents will allow developers to only perform nonclinical studies that are necessary to support functionality, follow distribution of the material and examine general safety/toxicity. However, as they are mainly focused on radiopharmaceuticals, companies are likely to apply knowledge of established testing packages to other new imaging agents and/or follow principles given in older regulatory guidelines, namely FDA’s “Guidance for Industry Developing Medical Imaging Drug and Biological Products Part I Conducting Safety Assessments”. Thus, in some cases, the need for regulatory agency interaction is still vital to avoid development surprises and delays due to an incomplete or badly performed testing package.
- 6 January 2020
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 54 (3) , 586-597
Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future
An examination for potential direct or indirect adverse effects on the immune system (immunotoxicity) is an established component of nonclinical testing to support safe use of new drugs. Testing recommendations occur in various regulatory guidance documents, especially ICH S8, and these will be presented. Key evaluation usually occurs in toxicology studies with further investigative work a consideration if a positive signal is seen. Expectations around whether findings may occur are related to the type of compound being developed, including a chemically synthesized small molecule, a small molecule oncology drug, a biopharmaceutical, an oligonucleotide, a gene therapy/stem cell product, a vaccine, or reformulation of drugs in liposomes or depots. Examples of immunotoxicity/immunogenicity findings will be discussed for all of these types of compound. Overall, it can be concluded that our main tool for evaluation of potential immunotoxicity/immunogenicity for a new drug still remains standard toxicology study testing with key assessment for effects on clinical pathology and lymphoid organs/tissues (weights and cellularity). Additional evaluation from studies using a T cell–dependent antibody response (TDAR) and lymphocyte phenotyping is also valuable, if needed. Thus, using the tools from the past, it is the role of toxicologists to work with clinical teams now and in the future, to interpret findings from nonclinical testing to possible adverse findings in humans.
- 6 January 2020
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 54 (3) , 586-597
Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future
An examination for potential direct or indirect adverse effects on the immune system (immunotoxicity) is an established component of nonclinical testing to support safe use of new drugs. Testing recommendations occur in various regulatory guidance documents, especially ICH S8, and these will be presented. Key evaluation usually occurs in toxicology studies with further investigative work a consideration if a positive signal is seen. Expectations around whether findings may occur are related to the type of compound being developed, including a chemically synthesized small molecule, a small molecule oncology drug, a biopharmaceutical, an oligonucleotide, a gene therapy/stem cell product, a vaccine, or reformulation of drugs in liposomes or depots. Examples of immunotoxicity/immunogenicity findings will be discussed for all of these types of compound. Overall, it can be concluded that our main tool for evaluation of potential immunotoxicity/immunogenicity for a new drug still remains standard toxicology study testing with key assessment for effects on clinical pathology and lymphoid organs/tissues (weights and cellularity). Additional evaluation from studies using a T cell–dependent antibody response (TDAR) and lymphocyte phenotyping is also valuable, if needed. Thus, using the tools from the past, it is the role of toxicologists to work with clinical teams now and in the future, to interpret findings from nonclinical testing to possible adverse findings in humans.
- 1 November 2019
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 108, 104441
Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development
- 1 November 2019
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 108, 104441
Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development